Tobira appoints Andrew Hindman president and CEO
This article was originally published in Scrip
Executive Summary
Tobira Therapeutics, a biopharmaceutical company focused on the development and commercialisation of therapies for HIV infection, has appointed Andrew Hindman president and chief executive officer. He most recently served as senior vice-president of corporate development at Nodalit, a biotech company developing molecular diagnostics and personalised medicine. Before that, he was vice-president of corporate development at Onyx Pharmaceuticals.